Folks, Vericel announced today that it received FDA Fast Track designation for its ixmyelocel‑T product for treatment of advanced heart failure due to dilated cardiomyopathy.
So why am I posting this news about Vericel on this board?
Let's compare Mesoblast to Vericel.
Back in April 2016, Vericel's ixmyelocel‑T product failed to meet it's secondary endpoints of heart-pumping efficiency and six-minute walking distance in the Phase 2b trial.
You read that right - it FAILED to meet it's secondary endpoints. And that was in the Phase 2b trial.
Plus, ixmyelocel‑T is autologous, which means it takes a patient's own stem cells.
As opposed to allogeneic, which is Mesoblast's products. Lookup the comparison advantages of allogeneic vs. autologous especially with respect to mass commercialization and ready, off-the-shelf availability.
Mesoblast's CHF therapy is light years ahead of Vericel's in its efficacy and commercial viability.
And Mesoblast is way past Phase 2 in CHF.
So. The. FDA. Just. Granted. Vericel. Fast. Track. Designation for its ixmyelocel‑T product.
Over and out.
Tick, tock, tick, tock..............
Heart Failure
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.015(1.38%) |
Mkt cap ! $1.227B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.10 | $1.06 | $3.236M | 3.021M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 13305 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 148487 | 18 |
View Market Depth
| Last trade - 14.55pm 20/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |